Shares of CureVac (NASDAQ: CVAC) were down 9.1% as of 2:45 p.m. ET Thursday after a German court temporarily suspended the biopharmaceutical company's patent trial against BioNTech (NASDAQ: BNTX).

CureVac previously failed to develop a successful COVID-19 vaccine during the pandemic, opting instead to focus on potential second-generation vaccines in partnership with GlaxoSmithKline. BioNTech, by contrast, generated tens of billions of dollars in annual revenue from its successful mRNA vaccines developed in partnership with . 

CureVac subsequently filed a lawsuit in Germany against BioNTech in July 2022, seeking "fair compensation" for infringement of its intellectual property rights based on over two decades of work on mRNA technology.

Continue reading

Source Fool.com